Brainomix, a global leader and pioneer of AI-powered imaging tools in lung fibrosis and stroke, today announced it was ...

The phase 2a trial showed GR-0621 met primary and secondary endpoints, demonstrating safety and efficacy over 12 weeks. Phase 2a data show oral GRI-0621 was safe and improved immune and fibrosis ...

-- BI 765423 has been developed to target IL-11, a key driver of fibrosis -- New study will investigate potential of BI 765423 to improve lung function for patients with idiopathic pulmonary fibrosis ...

Interim data from Phase 1 with single and multiple ascending doses show no safety signals and a generally favorable tolerability profile of ...

Pulmonary fibrosis is a lung disease where the air sacs and tissue in the lungs get stiff and scarred. This makes it harder to breathe and perform everyday activities. The damage tends to get worse ...

Nerandomilast improved FVC in the FIBRONEER-ILD trial, meeting its primary end point in patients with progressive pulmonary fibrosis. Safety and tolerability results were consistent with previous ...

Animate Biosciences today announces positive preclinical results from a mouse model of pulmonary fibrosis demonstrating that ...

Researchers at Tulane University have identified a potential new way to treat idiopathic pulmonary fibrosis (IPF), a deadly and currently incurable lung disease that affects more than 3 million people ...

Cystic fibrosis causes a buildup of mucus in the lungs that can lead to infection, and often death in children and young ...

Pulmonary fibrosis is a deadly disease in which the lungs become thickened and scarred, gradually losing their ability to deliver oxygen to the body. Now, scientists at UC San Francisco have ...